Abstract
Pertinent to pandemic obesity, the discovery of endogenous peptides that affect the ingestion of food has led to the question of how these ingestive peptides exert their actions in the brain. Whereas peripheral sources provide a ready reserve, the availability of ingestive peptides to their central nervous system targets can be regulated by the blood-brain barrier (BBB). Some of the peptides/polypeptides are transported by saturable mechanisms from blood to brain. Examples include leptin, insulin, mahogany, and pancreatic polypeptide. Some enter the brain by passive diffusion, such as neuropeptide Y, orexin A, cocaine- and amphetamine-regulated transcript, cyclo His-Pro, and amylin. Some others may have essentially no penetration of the BBB; this class includes agouti-related protein, melanin-concentrating hormone, and urocortin. The regulatory function of the BBB can be seen in various physiological states. Hyperglycemia may upregulate transport systems for leptin, urocortin, and galanin-like peptide, whereas fasting can down-regulate those for leptin and galanin-like peptide. Thus, the BBB plays a dynamic role in modulating the passage of ingestive peptides from blood to brain.
Keywords: Blood-brain barrier, feeding, leptin, obesity, transport.
CNS & Neurological Disorders - Drug Targets
Title:Involvement of the Blood-Brain Barrier in Metabolic Regulation
Volume: 15 Issue: 9
Author(s): Abba J. Kastin and Weihong Pan
Affiliation:
Keywords: Blood-brain barrier, feeding, leptin, obesity, transport.
Abstract: Pertinent to pandemic obesity, the discovery of endogenous peptides that affect the ingestion of food has led to the question of how these ingestive peptides exert their actions in the brain. Whereas peripheral sources provide a ready reserve, the availability of ingestive peptides to their central nervous system targets can be regulated by the blood-brain barrier (BBB). Some of the peptides/polypeptides are transported by saturable mechanisms from blood to brain. Examples include leptin, insulin, mahogany, and pancreatic polypeptide. Some enter the brain by passive diffusion, such as neuropeptide Y, orexin A, cocaine- and amphetamine-regulated transcript, cyclo His-Pro, and amylin. Some others may have essentially no penetration of the BBB; this class includes agouti-related protein, melanin-concentrating hormone, and urocortin. The regulatory function of the BBB can be seen in various physiological states. Hyperglycemia may upregulate transport systems for leptin, urocortin, and galanin-like peptide, whereas fasting can down-regulate those for leptin and galanin-like peptide. Thus, the BBB plays a dynamic role in modulating the passage of ingestive peptides from blood to brain.
Export Options
About this article
Cite this article as:
Kastin J. Abba and Pan Weihong, Involvement of the Blood-Brain Barrier in Metabolic Regulation, CNS & Neurological Disorders - Drug Targets 2016; 15 (9) . https://dx.doi.org/10.2174/1871527315666160920124928
DOI https://dx.doi.org/10.2174/1871527315666160920124928 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Germ Cell Apoptosis: Relevance to Infertility and Contraception
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cannabinoid System as a Potential Target for Drug Development in the Treatment of Cardiovascular Disease
Current Vascular Pharmacology Bradykinin B2 receptors play a neuroprotective role in Hypoxia/reoxygenation injury related to pyroptosis pathway
Current Neurovascular Research Analysis of Edg-Like LPA Receptor-Ligand Interactions
Current Pharmaceutical Design Adrenergic and V1-ergic Agonists/Antagonists Affecting Recovery from Brain Trauma in the Lund Project Act on Astrocytes
Current Signal Transduction Therapy Recent Advances in the Imaging of Programmed Cell Death
Current Pharmaceutical Design Anti-VEGF Drugs in Eye Diseases: Local Therapy with Potential Systemic Effects
Current Pharmaceutical Design Subject index to volume 3
Current Molecular Medicine Cannabinoids and Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Efficient Synthesis of 6-O-methyl-scutellarein from Scutellarin via Selective Methylation
Letters in Organic Chemistry Serum Vitamin E (α-Tocopherol) Estimation: A Potential Biomarker of Antioxidant Status Evaluation on Heavy Metal Toxicities
Recent Patents on Biomarkers Nanotherapeutics in Neuropathologies: Obstacles, Challenges and Recent Advancements in CNS Targeted Drug Delivery Systems
Current Neuropharmacology Nutrition, Nitrogen Requirements, Exercise and Chemotherapy-Induced Toxicity in Cancer Patients. A puzzle of Contrasting Truths?
Anti-Cancer Agents in Medicinal Chemistry A Role for Endothelin-1 in Peripheral Vascular Disease
Current Vascular Pharmacology Microvascular Thrombosis: An Exciting but Elusive Therapeutic Target in Reperfused Acute Myocardial Infarction
Cardiovascular & Hematological Disorders-Drug Targets Astrocytes and Inflammasome: A Possible Crosstalk in Neurological Diseases
Current Medicinal Chemistry Pleiotropic Actions of PPARg Activators Thiazolidinediones in Cardiovascular Diseases
Current Pharmaceutical Design Nanofibre Based Smart Pharmaceutical Scaffolds for Wound Repair and Regenerations
Current Pharmaceutical Design Effects of LPA and S1P on the Nervous System and Implications for Their Involvement in Disease
Current Drug Targets Dietary Nitrite in Nitric Oxide Biology: A Redox Interplay with Implications for Pathophysiology and Therapeutics
Current Drug Targets